Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 302 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic dosing Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

NCT01482715
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
6
States / cities
San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

NCT03424135
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 7, 2026, 3:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of PF-06873600 in People With Cancer

NCT03519178
View directory record Official record
Conditions
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions
PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

NCT01686217
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Food Effect, Healthy Volunteers
Interventions
ASP015K ER, ASP015K IR
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 7, 2026, 3:42 PM EDT
Terminated Phase 1 Interventional Results available

A Study of PF-04217903 in Patients With Advanced Cancer

NCT00706355
View directory record Official record
Conditions
Neoplasms
Interventions
PF-04217903
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients

NCT02444143
View directory record Official record
Conditions
Kidney Transplantation
Interventions
tacrolimus extended release
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 7, 2026, 3:42 PM EDT
Not yet recruiting Phase 4 Interventional

Oral Antibiotic Pharmacokinetics in Young Infants

NCT07815613
View directory record Official record
Conditions
Linezolid Pharmacokinetics in Young Infants, Pharmacokinetic Analysis, Linezolid, Infant and Young Children
Interventions
Linezolid (LZD)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Days to 90 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 7, 2026, 3:42 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

NCT07349758
View directory record Official record
Conditions
Healthy Volunteer, HIV Prevention
Interventions
tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

NCT01794520
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Venetoclax, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
21
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Truvada Study

NCT03719053
View directory record Official record
Conditions
Medication Adherence, HIV Prevention
Interventions
Tenofovir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

NCT01380561
View directory record Official record
Conditions
Healthy
Interventions
asimadoline
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 56 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

NCT00306618
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
Panzem Nanocrystal Colloidal Dispersion
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2008 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children

NCT03668951
View directory record Official record
Conditions
Heart Diseases
Interventions
Dexmedetomidine buccal, Dexmedetomidine Intranasal
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 48 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Phase 1 Intrathecal Topotecan for Neoplastic Meningitis

NCT00674674
View directory record Official record
Conditions
Neoplastic Meningitis
Interventions
Topotecan
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

NCT01572662
View directory record Official record
Conditions
Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Diseases, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Fludarabine monophosphate, Busulfan, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
5 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

NCT01316055
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Dalfampridine-ER
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naproxen Sodium ER Pharmacokinetic Study

NCT00818415
View directory record Official record
Conditions
Pain
Interventions
Naproxen sodium ER (BAYH6689), Commercial Naproxen (Aleve, BAYH6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage in the Fed and Fasted States

NCT05266248
View directory record Official record
Conditions
Pharmacokinetics
Interventions
250 mg encapsulated caffeine
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

NCT02001571
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

NCT05333107
View directory record Official record
Conditions
Healthy Volunteers; High Cholesterol
Interventions
NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Cypress, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

NCT00712504
View directory record Official record
Conditions
Advanced Solid Tumors, Non Small Cell Lung Cancer
Interventions
sunitinib, docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2008 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

NCT00759928
View directory record Official record
Conditions
Refractory Solid Tumors
Interventions
Erlotinib, Sorafenib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Fort Myers, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Phenylephrine Pediatric Pharmacokinetic Study

NCT00762567
View directory record Official record
Conditions
Rhinitis
Interventions
phenylephrine HCl
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Oct 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

NCT05162053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
vicagrel Capsules, Clopidogrel Tablets
Drug
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 7, 2026, 3:42 PM EDT